Emanuela Paternò

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

The prognostic role of tumor size in early breast cancer in the era of molecular biology

Anaid Anna Kasangian, Giorgio Gherardi, Elena Biagioli et al. · PLoS ONE · 2017 · 42 citations · Full text

Medicine, Oncology, Surgery +14

Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma

Anna Guidetti, Arabella Mazzocchi, Rosalba Miceli et al. · Leukemia Research · 2017 · 25 citations

Medicine, Hematology, Oncology +5

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Marina Elena Cazzaniga, Mario Airoldi, Valentina Arcangeli et al. · The Breast · 2017 · 23 citations · Full text

Medicine, Oncology, Pharmacology +16

Comparison of the Effects of Carvedilol and Nifedipine in Patients with Essential Hypertension and Non-Insulin-Dependent Diabetes Mellitus

F. Albergati, Emanuela Paternò, Robert Venuti et al. · Journal of Cardiovascular Pharmacology · 1992 · 15 citations

Pharmacy, Pharmacology, Pharmacotherapy +16